National summit convened to reduce overuse of unnecessary procedures and treatments.
The American Medical Association and The Joint Commission co-sponsored the “National Summit on Overuse” on September 24, 2012 to identify appropriate use of procedures that often are overused. These procedures include placing heart stents, blood product transfusions, placing tympanostomy ear tubes for brief periods of time to relieve fluid behind the ear drum, prescribing antibiotics for viral upper respiratory infections, and early induction of scheduled births. Probably the most problematic of these overused procedures is antibiotic treatment of viral illnesses. This is due in part to prescribers over-prescribing antibiotics, but also due to healthcare consumers who either insist on obtaining antibiotics or take someone else’s (or leftover) antibiotics when cold and flu symptoms occur.
At the summit, physician organizations, medical specialties, government agencies, research institutions, and patient groups gathered to discuss the appropriate use of the treatments and procedures. They identified ways to raise awareness among to reduce overuse and educate healthcare providers and the public about appropriate. For some of these topics, solutions are known or guidelines already exist, but need to be more widely communicated. For others, more analysis and research is needed. Recommendations from the summit includes raising awareness through education; keeping the patient at the center of all discussions; collaborating with all stakeholders; conducting research to address identified gaps; aligning guidelines in situations where multiple guidelines exist; and coordinating policies, benefits, and payment incentives.
The complete list of recommendations is available at http://www.ama-assn.org/resources/doc/cqi/national-summit-overuse-summary.pdf.
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
May 8th 2024Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.
Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma
May 6th 2024Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.